Silvana Pilotti

23.5k total citations · 2 hit papers
294 papers, 16.2k citations indexed

About

Silvana Pilotti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Silvana Pilotti has authored 294 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Pulmonary and Respiratory Medicine, 110 papers in Oncology and 74 papers in Molecular Biology. Recurrent topics in Silvana Pilotti's work include Sarcoma Diagnosis and Treatment (84 papers), Cancer-related Molecular Pathways (25 papers) and Gastrointestinal Tumor Research and Treatment (24 papers). Silvana Pilotti is often cited by papers focused on Sarcoma Diagnosis and Treatment (84 papers), Cancer-related Molecular Pathways (25 papers) and Gastrointestinal Tumor Research and Treatment (24 papers). Silvana Pilotti collaborates with scholars based in Italy, United States and France. Silvana Pilotti's co-authors include Marco A. Pierotti, Alessandro Gronchi, Paolo G. Casali, Maria Grazia Daidone, Franco Rilke, Gabriella Sozzi, Federica Perrone, Elena Tamborini, Paola Collini and Aurora Costa and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Silvana Pilotti

294 papers receiving 15.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation and In vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties

2005 1.4k citations Silvana Pilotti, Marco A. Pierotti et al. Cancer Research profile →
High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma

2006 507 citations Lisa Licitra, Federica Perrone et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvana Pilotti Italy	68	6.6k	5.3k	5.1k	2.7k	2.7k	294	16.2k
Jonathan A. Fletcher United States	75	5.5k 0.8×	11.0k 2.1×	7.2k 1.4×	2.3k 0.9×	2.5k 0.9×	203	23.4k
Lee J. Helman United States	67	4.0k 0.6×	5.0k 0.9×	7.0k 1.4×	1.6k 0.6×	2.4k 0.9×	208	14.3k
Michael P. LaQuaglia United States	61	3.4k 0.5×	5.4k 1.0×	3.6k 0.7×	1.5k 0.6×	1.7k 0.6×	325	13.3k
Yoshinao Oda Japan	64	8.7k 1.3×	7.7k 1.4×	6.3k 1.2×	2.4k 0.9×	2.8k 1.1×	948	20.4k
Noel Weidner United States	49	5.4k 0.8×	4.3k 0.8×	8.8k 1.7×	2.0k 0.7×	5.5k 2.1×	183	17.9k
Giovanni Tallini Italy	65	3.7k 0.6×	3.2k 0.6×	4.5k 0.9×	2.6k 1.0×	2.4k 0.9×	288	14.6k
Antoîne Italiano France	67	9.0k 1.4×	9.2k 1.7×	4.0k 0.8×	2.6k 1.0×	2.2k 0.8×	618	17.5k
Marco A. Pierotti Italy	85	10.7k 1.6×	5.5k 1.0×	13.3k 2.6×	3.9k 1.4×	5.5k 2.1×	457	27.2k
Yoshihiro Matsuno Japan	59	5.2k 0.8×	5.6k 1.0×	2.7k 0.5×	2.3k 0.9×	1.5k 0.6×	381	13.0k
Allen M. Gown United States	68	6.4k 1.0×	3.8k 0.7×	5.0k 1.0×	2.3k 0.9×	3.7k 1.4×	191	16.1k

Countries citing papers authored by Silvana Pilotti

Since Specialization

Citations

This map shows the geographic impact of Silvana Pilotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Pilotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Pilotti more than expected).

Fields of papers citing papers by Silvana Pilotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Pilotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Pilotti. The network helps show where Silvana Pilotti may publish in the future.

Co-authorship network of co-authors of Silvana Pilotti

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Pilotti. A scholar is included among the top collaborators of Silvana Pilotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Pilotti. Silvana Pilotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frapolli, Roberta, Ezia Bello, Ilaria Craparotta, et al.. (2019). Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. Clinical Cancer Research. 25(24). 7565–7575. 20 indexed citations

Cecco, Loris De, Carla Facco, Roberta Granata, et al.. (2019). A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. Oral Oncology. 90. 94–101. 10 indexed citations

Cecco, Loris De, Matteo Dugo, Gian Paolo Dagrada, et al.. (2018). The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response. Cancer Communications. 38(1). 70–70. 23 indexed citations

Bossi, Paolo, Marco Siano, Cristiana Bergamini, et al.. (2017). Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers. 2017. 1–9. 6 indexed citations

Colombo, Chiara, Antonino Belfiore, Loris De Cecco, et al.. (2017). β‐Catenin in desmoid‐type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Molecular Oncology. 11(11). 1495–1507. 26 indexed citations

Magnaghi, Paola, Barbara Salom, Liviana Cozzi, et al.. (2017). Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury. Molecular Cancer Therapeutics. 17(3). 603–613. 59 indexed citations

Meazza, Cristina, Antonino Belfiore, Adele Busico, et al.. (2016). AKT1 and BRAF mutations in pediatric aggressive fibromatosis. Cancer Medicine. 5(6). 1204–1213. 24 indexed citations

Bossi, Paolo, Cristiana Bergamini, Marco Siano, et al.. (2016). Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research. 22(15). 3961–3970. 53 indexed citations

Gasparotto, Daniela, Sabrina Rossi, Maurizio Polano, et al.. (2016). Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. Clinical Cancer Research. 23(1). 273–282. 60 indexed citations

10.

Stacchiotti, Silvia, Annalisa Astolfi, Alessandro Gronchi, et al.. (2016). Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial–Mesenchymal Transition–like Process and 22q Loss. Molecular Cancer Research. 14(9). 820–829. 23 indexed citations

11.

Reid, James F., Eugenio Zoni, Andrea Lampis, et al.. (2012). miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. Molecular Cancer Research. 10(4). 504–515. 114 indexed citations

12.

Miranda, Claudia, Francesca Molinari, Elena Conca, et al.. (2012). KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research. 18(6). 1769–1776. 145 indexed citations

13.

Negri, Tiziana, Eva Tarantino, Marta Orsenigo, et al.. (2010). Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes and Cancer. 49(10). 901–909. 39 indexed citations

14.

Negri, Tiziana, Emanuela Virdis, Silvia Brich, et al.. (2010). Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma. Clinical Cancer Research. 16(14). 3581–3593. 37 indexed citations

15.

Forni, Cristiana, Mario Minuzzo, Emanuela Virdis, et al.. (2009). Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Molecular Cancer Therapeutics. 8(2). 449–457. 142 indexed citations

16.

Modena, Piergiorgio, Elena Lualdi, Federica Facchinetti, et al.. (2005). SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas. Cancer Research. 65(10). 4012–4019. 241 indexed citations

17.

Moliterni, Angela, Sylvie Ménard, Pinuccia Valagussa, et al.. (2003). HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. Journal of Clinical Oncology. 21(3). 458–462. 76 indexed citations

18.

Balsari, Andrea, Patrizia Casalini, Elda Tagliabue, et al.. (1999). Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. American Journal Of Pathology. 155(5). 1543–1547. 20 indexed citations

19.

Ménard, Sylvie, Patrizia Casalini, Gorana Tomasic, et al.. (1999). Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment. 55(2). 167–175. 44 indexed citations

20.

Alzani, Rachele, Marco A. Pierotti, Sylvie Ménard, et al.. (1988). Monoclonal Antibodies Against NIH 3T3 Cells Transformed by Human Thyroid Carcinoma DNA. Hybridoma. 7(1). 7–18. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact